Abstract:Depression is the most prevalent mental disorder in the world associated with huge socio-economic consequences. While depressive-related symptoms are well known, the molecular mechanisms underlying disease pathophysiology and progression remain largely unknown. The gut microbiota (GM) is emerging as a key regulator of the central nervous system homeostasis by exerting fundamental immune and metabolic functions. In turn, the brain influences the intestinal microbial composition through neuroendocrine signals, within the so-called gut microbiota-brain axis. The balance of this bidirectional crosstalk is important to ensure neurogenesis, preserve the integrity of the blood-brain barrier and avoid neuroinflammation. Conversely, dysbiosis and gut permeability negatively affect brain development, behavior, and cognition. Furthermore, although not fully defined yet, changes in the GM composition in depressed patients are reported to influence the pharmacokinetics of common antidepressants by affecting their absorption, metabolism, and activity. Similarly, neuropsychiatric drugs may shape in turn the GM with an impact on the efficacy and toxicity of the pharmacological intervention itself. Consequently, strategies aimed at re-establishing the correct homeostatic gut balance (i.e., prebiotics, probiotics, fecal microbiota transplantation, and dietary interventions) represent an innovative approach to improve the pharmacotherapy of depression. Among these, probiotics and the Mediterranean diet, alone or in combination with the standard of care, hold promise for clinical application. Therefore, the disclosure of the intricate network between GM and depression will give precious insights for innovative diagnostic and therapeutic approaches towards depression, with profound implications for drug development and clinical practice.

The Microbiota-Gut-Brain Axis: A New Direction in Research on Depression

Epigenetics in depression and gut-brain axis: A molecular crosstalk

The Microbiota–Gut–Brain Axis in Depression: The Potential Pathophysiological Mechanisms and Microbiota Combined Antidepression Effect

Gut-brain axis: A matter of health and disease in neuropsychiatric disorders…!

Brain–gut–microbiota axis in depression: A historical overview and future directions

Mood and Microbes: a Comprehensive Review of Intestinal Microbiota’s Impact on Depression

Prebiotic and Probiotic Modulation of the Microbiota–Gut–Brain Axis in Depression

The microbiota-gut-brain axis in pathogenesis of depression: a narrative review

Mood and microbes: a comprehensive review of intestinal microbiota's impact on depression

New perspectives on microbiome-dependent gut-brain pathways for the treatment of depression with gastrointestinal symptoms: from bench to bedside

Gut-brain axis: A matter of concern in neuropsychiatric disorders ...!

Depression-associated gut microbes, metabolites and clinical trials

The Gut-Brain-Microbiome Connection: Can Probiotics Decrease Anxiety and Depression?

Gut-brain axis in depression: Crosstalk between neuroinflammation and gut microbiota

Reviewing the role of gut microbiota in the pathogenesis of depression and exploring new therapeutic options

Mechanistic Insights into the Link between Gut Dysbiosis and Major Depression: An Extensive Review

Intestinal Barrier, Immunity and Microbiome: Partners in the Depression Crime

Research progress on intestinal flora and depression

The brain-gut-microbiota interplay in depression: A key to design innovative therapeutic approaches

The Gut-Brain Axis and Its Role in Depression

Gut-to-brain axis provides novel therapeutic targets for depression